Our Technologies
We have developed technology platforms to unlock high-value drug classes, targets, and modalities, including transmembrane proteins and T-cell engagers.
We are using our platform to develop first-in-class antibody medicines for well-validated complex transmembrane protein targets that have been intractable using traditional approaches.
Learn More
Our T-cell engager platform leverages hundreds of diverse CD3-binding antibodies to create bispecific antibodies that achieve potent tumor-cell killing with reduced cytokine release, which can help address dose-limiting toxicities.
Learn MoreOur engine integrates teams, technology, infrastructure, and data science to move therapeutic programs from concept to the clinic.
We are advancing programs our first two programs through IND-enabling studies, and are currently integrating process development, manufacturing, and regulatory capabilities into our engine.
We use genetic, cell, and/or protein approaches to immunize multiple species, including rats, wild-type and humanized mice platforms (ATX-Gx™, Trianni® platform and Trianni Mouse® ), camelids, and more.
High-throughput single-cell screening powered by machine vision and high-throughput sequencing.
Lead panel identification by high-throughput functional and biophysical characterization.
Development candidate selection supported by mid-scale expression and detailed characterization.
Clinical candidate selection with large-scale expression, IND-enabling studies, and CMC development.
A 124,000 sqft clinical manufacturing facility with capabilities for GMP cell banking and production of GMP drug substance (up to 2,000 L bioreactors).